Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Sahlgrenska University Hospital
UNICANCER
Institut de Cancérologie de Lorraine
Beijing Health Guard Biotechnology, Inc
Ciusss de L'Est de l'Île de Montréal
Canadian Cancer Trials Group
Johns Hopkins Bloomberg School of Public Health
Alliance for Clinical Trials in Oncology
INSYS Therapeutics Inc
National Cancer Institute (NCI)